Literature DB >> 6743355

Binding of oxprenolol and propranolol to serum, albumin and alpha 1-acid glycoprotein in man and other species.

F M Belpaire, R A Braeckman, M G Bogaert.   

Abstract

Species differences in binding of basic drugs have only occasionally been studied and we have therefore measured the binding of the beta-adrenergic blockers oxprenolol and propranolol in (1) serum of healthy humans, dogs, rats and rabbits and of rabbits with experimental arthritis, (2) a solution of albumin of these species and (3) a solution of human alpha 1-AGP. In humans, dogs, rats and arthritic rabbits, binding of oxprenolol and propranolol was much higher in serum than in albumin solution; in healthy rabbits serum binding was very low and not different from albumin binding. For both drugs, concentration-dependency was seen in serum of dogs, humans and rats and of arthritic rabbits; a similar concentration-dependency was found for human alpha 1-AGP solution, but not for human albumin and for serum of healthy rabbits. Tris (2-butoxyethyl)-phosphate (TBEP), a known displacer of drugs from alpha 1-AGP in humans, decreased binding in serum of all species except the rabbit. For both beta-blockers, species differences in capacity constants were found; species differences in affinity constants were present only for propranolol. These results suggest that in humans, dog and rat, but much less in rabbits, oxprenolol and propranolol bind mainly to alpha 1-AGP and that binding to alpha 1-AGP is more important for oxprenolol than for propranolol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743355     DOI: 10.1016/0006-2952(84)90575-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Binding of prazosin and propranolol at variable alpha 1-acid glycoprotein and albumin concentrations.

Authors:  G Sager; R Jaeger; C Little
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

3.  Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.

Authors:  Amina Haouala; Nicolas Widmer; Monia Guidi; Michael Montemurro; Serge Leyvraz; Thierry Buclin; Chin B Eap; Laurent A Decosterd; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

4.  Species differences of serum albumins: I. Drug binding sites.

Authors:  T Kosa; T Maruyama; M Otagiri
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

5.  Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein.

Authors:  F Herve; E Gomas; J C Duche; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

6.  Effect of probenecid on the enantioselective pharmacokinetics of oxprenolol and its glucuronides in the rabbit.

Authors:  M E Laethem; F M Belpaire; P Wijnant; M G Bogaert
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

7.  A study of the interaction between ropranolol and NSAIDs in protein binding by gel filtration method.

Authors:  Rezaei Zahra; Raissi Ahmad; Moshtaghi S Ali Asghar; Asadipour Ali; Khabnadideh Soghra
Journal:  Indian J Clin Biochem       Date:  2006-03

8.  Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.

Authors:  Tomoki Takechi; Tadao Kumokawa; Rumiko Kato; Takeshi Higuchi; Tsuyoshi Kaneko; Ichiro Ieiri
Journal:  J Clin Pharmacol       Date:  2018-05-10       Impact factor: 3.126

Review 9.  Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein.

Authors:  Sherri A Smith; Nigel J Waters
Journal:  Pharm Res       Date:  2018-12-28       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.